Gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC), particularly when of advanced stage, can present challenges in management, and often poor prognosis. However, advancements in treatment by targeting molecular drivers, particularly HER2, can lead to better outcomes in HER2-overexpressing tumors.

Learn about the latest approaches for HER2 assessment and guideline-based recommendations, including diagnostic criteria and treatment advances for managing HER2-positive advanced GEA and BTC, by exploring resources within the portal. Please also avail of our high-definition educational animations and virtual reality tools found within the HD Visual Learning section.